

Diabetic Neuropathy R&D Pipeline Analysis Report, Q4 2020

<https://marketpublishers.com/r/DD79A215F627EN.html>

Date: October 2020

Pages: 142

Price: US\$ 1,699.00 (Single User License)

ID: DD79A215F627EN

Abstracts

Diabetic Neuropathy Pipeline Overview

The Q4 Diabetic Neuropathy pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under development for Diabetic Neuropathy, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company profiles including their business information, and market developments.

Diabetic Neuropathy Disease Types, Symptoms, Causes, and Available Treatment Options

The comprehensive report on the indication presents Diabetic Neuropathy disease overview, Diabetic Neuropathy types, Diabetic Neuropathy symptoms, causes, and FDA/EMA approved treatment options.

Diabetic Neuropathy Pipeline Trends and Insights

The year 2020 witnessed progress in innovations and the number of pipeline agents researched for Diabetic Neuropathy indication. The report presents near-term and long-term pipeline development trends and potential insights.

Diabetic Neuropathy Company Trends and Insights

The report analyzes the development progress, current status, investments, partnerships, and other developments of 29 companies. Business profiles and contact details of the companies actively perusing Diabetic Neuropathy pipeline are assessed.

Diabetic Neuropathy R&D Pipeline Development Phase Trends and Insights

From the discovery stage of development to phase 3 development, all the potential

pipeline drug candidates are analyzed in the report. Diabetic Neuropathy discovery stage, research stage, Phase 1, phase 2, Phase 3, IND enabling studies are provided in the research.

Small Diabetic Neuropathy companies look for licensing and collaboration partners. High R&D costs and long duration pose challenges for small companies operating in the industry. Further, the presence of large companies and stringent regulations act as barriers for Diabetic Neuropathy pipeline development companies. Accordingly, a significant portion of small companies presents potential licensing and collaboration opportunities.

Diabetic Neuropathy Pipeline Market News and Developments during 2020

The Diabetic Neuropathy industry news, pipeline research, market developments including advancement in phases, pre-clinical study results, clinical trial launches, acquisitions and mergers, regulatory approvals, and others are included in the report.

Diabetic Neuropathy Mechanism of Action and Targets

Leading Mechanism of Action and targets being researched by all the companies and their progress is included. New mechanisms of actions introduced during the year, route of administration, orphan drug designation, and others are provided in the study.

New molecular entity details

Drug candidates identified as new molecular entities by FDA, EMA, and other regulators are included in the research.

Sources and Research Methodology

Data is updated daily across diseases in the infectious pipeline service. We review our quarterly pipeline reports for the latest 5 years to present longitudinal insights.

Scope and Coverage

Diabetic Neuropathy pipeline development activities across the early phase, mid-stage, and late phase pipelines including therapeutic candidates

Drug profiles comprising of drug overview, mechanism of action, co-developers, originators, route of administration, molecule type, orphan drug status, new molecular entity, area, and other details.

Company-company partnerships, company-institute partnerships, and

investment details of companies are included

29 companies are included including Achelios Therapeutics Inc, Angelini Group, Arena Pharmaceuticals Inc, Bionevia Pharmaceuticals, Breath of Life International Pharma Ltd, Bristol-Myers Squibb Co, Calchan Ltd, Celularity Inc, Commence Bio Inc, CSPC Pharmaceutical Group Ltd, Exodos Life Sciences Ltd, Glycadia Inc, GNT Pharma Co Ltd, Grifols SA, Grunenthal GmbH, Immune Pharmaceuticals Inc, Kineta Inc, Medifron DBT Co Ltd, Mitsubishi Tanabe Pharma Corp, Omeros Corp, Pfizer Inc, Praetego Inc, Reata Pharmaceuticals Inc, Seneca Biopharma Inc, Sichuan Haisco Pharmaceutical Co Ltd, Sonnet BioTherapeutics Holdings Inc, Sphaera Pharma Pte Ltd, WEX Pharmaceuticals Inc, Winsantor Inc,

Disease overview, Pipeline trends, market analysis, and other developments

Potential licensing/new business opportunities in Diabetic Neuropathy pipeline market

Highlights

Global coverage of companies and pipeline agents

2020 Trends, market analysis, and developments

Potential growth opportunities

Comprehensive details of drug candidates

Reasons to Buy

Drive pipeline research and commercial assessment

Assess most promising drug candidates and stay ahead of the competition

Strengthen your pipeline through identifying business expansion and acquisition opportunities

Develop new candidates based on most focused targets and mechanism of actions

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. DIABETIC NEUROPATHY PIPELINE TRENDS AND INSIGHTS

- 2.1 Dominant Phase type of Diabetic Neuropathy Pipeline, 2020
- 2.2 Most focused Mechanism of Action in Diabetic Neuropathy Pipeline
- 2.3 Leading type of Route of Administration during 2020
- 2.4 Proportion of New Molecular Entities in Diabetic Neuropathy pipeline
- 2.5 Active Companies Developing Diabetic Neuropathy pipeline

3. DIABETIC NEUROPATHY DISEASE TYPES, SYMPTOMS, CAUSES, AND AVAILABLE TREATMENT OPTIONS

- 3.1 Disease Overview
- 3.2 Types
- 3.3 Symptoms
- 3.4 Approved Treatment Options

4. DIABETIC NEUROPATHY PIPELINE COMPANY TRENDS AND INSIGHTS - BUSINESS PROFILES, DRUG CANDIDATES AND CONTACTS

- 4.1 Achelios Therapeutics Inc
- Angelini Group
- Arena Pharmaceuticals Inc
- Bionevia Pharmaceuticals
- Breath of Life International Pharma Ltd
- Bristol-Myers Squibb Co
- Calchan Ltd
- Celularity Inc
- Commence Bio Inc
- CSPC Pharmaceutical Group Ltd
- Exodos Life Sciences Ltd
- Glycadia Inc
- GNT Pharma Co Ltd

Grifols SA
Grunenthal GmbH
Immune Pharmaceuticals Inc
Kineta Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Omeros Corp
Pfizer Inc
Praetego Inc
Reata Pharmaceuticals Inc
Seneca Biopharma Inc
Sichuan Haisco Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
WEX Pharmaceuticals Inc
Winsantor Inc

5. DIABETIC NEUROPATHY PIPELINE DRUG PROFILES

5.1 Current Status of Drug and Vaccine Candidates

5.2 Drug Snapshot

5.2.1 Drug

5.2.2 Mechanism of Action

5.2.3 Phase

5.2.4 Co-Developer

5.2.5 Originator

5.2.6 Synonym

5.2.7 Route of Administration

5.2.8 Type of Molecule

5.2.9 Orphan Drug Status

5.2.10 New Molecular Entity

5.2.11 Area

5.3 Drug Details

5.4 Mechanism of Action

5.5 Licensing/Collaboration Agreements

5.6 Clinical Trial Details

6. DIABETIC NEUROPATHY PIPELINE MARKET NEWS AND DEVELOPMENTS DURING 2020

7. APPENDIX

7.1 About the Publisher

7.2 Sources and Research Methodology

I would like to order

Product name: Diabetic Neuropathy R&D Pipeline Analysis Report, Q4 2020

Product link: <https://marketpublishers.com/r/DD79A215F627EN.html>

Price: US\$ 1,699.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DD79A215F627EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970